查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1452446

血糖仪市场-按产品（自我监测血糖仪、连续血糖监测仪[可穿戴式、非可穿戴式]）、应用（1 型、2 型和妊娠糖尿病）、配销通路（医院、零售、在线）-全球预测, 2024-2032

Glucometer Market - By Product (Self-monitoring Blood Glucose Meter, Continuous Glucose Monitor [Wearable, Non-wearable]), Application (Type 1, Type 2, & Gestational Diabetes), Distribution Channel (Hospital, Retail, Online)-Global Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 223 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在糖尿病管理领域持续研发活动的推动下，2024 年至 2032 年全球血糖仪市场规模将达到 12.8% 的CAGR。随着研究人员开发创新技术并提高血糖仪的准确性和效率，医疗保健提供者和糖尿病患者正在寻求先进的解决方案。例如，2024 年 3 月，印度理工学院曼迪分校的研究人员推出了突破性的设备，无需血液样本即可检测糖尿病。该设备被称为非侵入式血糖仪，透过分析气球中的呼吸样本来发挥作用，为传统方法提供无痛且有效的替代方案。

随着对个人化医疗保健和主动疾病管理的日益重视，对具有先进功能的血糖仪的需求将继续增长，以塑造糖尿病护理的模式。持续血糖监测、无线连接和智慧型手机整合等增强功能的持续努力也将推动市场成长。

整个血糖仪产业分为产品类型、应用、配销通路和地区。

从产品类型来看，自我监测血糖仪细分市场的市场份额将显着发展，2024年至2032年的CAGR将达到15%。这些设备使糖尿病患者能够在家中或在家中方便、准确地监测自己的血糖水平。在旅途中。随着全球糖尿病盛行率的不断上升，对有效的自我管理工具的需求日益增长。自我监测血糖仪可以让使用者即时了解自己的血糖水平，以便主动管理自己的病情。随着人们优先考虑主动健康监测，自我监测血糖仪的需求将持续稳定成长。

根据应用情况，2024年至2032年，1型糖尿病领域的血糖仪产业收入复合CAGR将达到12.4%。由于第1型糖尿病需要定期监测血糖水平以有效管理胰岛素剂量，因此血糖仪在日常管理中发挥着至关重要的作用例行公事。这些设备为使用者提供有关血糖水平的即时回馈，从而能够及时采取干预措施以保持最佳健康状况。随着全球 1 型糖尿病盛行率不断上升，针对此类患者量身定制的准确、可靠的血糖仪的需求将进一步增加。

亚太地区血糖仪市场从2024年到2032年将呈现13.5%的CAGR。随着糖尿病盛行率的不断上升以及人们对主动医疗保健管理的日益关注，该地区对血糖仪的需求不断增加，以便个人能够方便地监测血糖水平并有效地进行疾病管理。医疗保健基础设施和意识的改善进一步推动了针对亚太地区人口多样化需求的血糖仪的需求。例如，2023 年10 月，印度孟买州政府决定允许1-12 年级患有1 型糖尿病的学生在教室和考场食用零食和药物，并配备血糖仪，这一决定受到了学校、家长和学生的热烈欢迎。和非政府组织。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 全球糖尿病盛行率上升
      • 技术进步
      • 全球对自我监控设备的需求不断增长
      • 政府为提高人们的意识而采取的倡议
    • 产业陷阱与挑战
      • 先进设备及配件成本高
      • 缺乏报销和严格的规定
  • 成长潜力分析
  • 技术景观
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略展望矩阵

第 5 章：市场估计与预测：按产品类型，2018 年 - 2032 年

  • 主要趋势
  • 自我监测血糖仪
  • 连续血糖监测仪
    • 穿戴式
    • 不可穿戴

第 6 章：市场估计与预测：按应用，2018 - 2032

  • 主要趋势
  • 1 型糖尿病
  • 2型糖尿病
  • 妊娠糖尿病

第 7 章：市场估计与预测：按配销通路，2018 年 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网上销售
  • 糖尿病诊所和中心

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 波兰
    • 瑞士
    • 瑞典
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 印尼
    • 泰国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 智利
    • 秘鲁
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 科威特
    • 阿联酋
    • 土耳其
    • 埃及
    • 以色列
    • 卡达
    • 中东和非洲其他地区

第 9 章：公司简介

  • Abbott Laboratories
  • AgaMatrix
  • All Medicus Co., Ltd.
  • Ascensia Diabetes Care Holdings AG
  • Arkray, Inc.
  • B. Braun Melsungen AG
  • Bionime Corporation
  • DarioHealth Corporation
  • Dexcom, Inc.
  • Essenlife Bioscience, Inc.
  • F. Hoffmann-La Roche Ltd.
  • LifeScan Inc.
  • Medtronic plc
  • Nova Biomedical, Inc.
  • Sinocare Inc.
简介目录
Product Code: 8010

Global Glucometer Market size will witness 12.8% CAGR between 2024 and 2032 propelled by the ongoing R&D activities in the field of diabetes management. As researchers develop innovative technologies and improve the accuracy and efficiency of glucometers, healthcare providers and individuals with diabetes are seeking advanced solutions. For instance, in March 2024, researchers at IIT Mandi introduced a groundbreaking device capable of detecting diabetes without the necessity of blood samples. Termed as a non-invasive glucometer, this device functions by analyzing breath samples contained in a balloon for providing a painless and effective alternative to conventional methods.

With a growing emphasis on personalized healthcare and proactive disease management, the demand for glucometers with advanced capabilities will continue to rise for shaping the landscape of diabetes care. Rising efforts towards enhanced features, such as continuous glucose monitoring, wireless connectivity, and smartphone integration will also drive the market growth.

The overall glucometer industry is classified into product type, application, distribution channel and region.

In terms of product type, the market share from the self-monitoring blood glucose meters segment will undergo significant development, depicting 15% CAGR from 2024 to 2032. These devices empower individuals with diabetes to monitor their blood glucose levels conveniently and accurately at home or on the go. With the increasing prevalence of diabetes worldwide, there is a growing need for effective self-management tools. Self-monitoring blood glucose meters offer users real-time insights into their glucose levels for facilitating proactive management of their condition. With individuals prioritizing proactive health monitoring, the demand for self-monitoring blood glucose meters will continue to grow steadily.

Based on application, the glucometer industry revenue from the type 1 diabetes segment will register a 12.4% CAGR from 2024 to 2032. As type 1 diabetes requires regular monitoring of blood glucose levels to manage insulin dosages effectively, glucometers play a crucial role in daily management routines. These devices provide users with real-time feedback on their glucose levels, enabling timely interventions to maintain optimal health. With the rising prevalence of type 1 diabetes globally, the demand for accurate and reliable glucometers tailored to the needs of individuals with this condition will further increase.

Asia pacific glucometer market will showcase a 13.5% CAGR from 2024 to 2032. With a growing prevalence of diabetes and an increasing focus on proactive healthcare management, there is a heightened demand for glucometers in the region to enable individuals to monitor their blood glucose levels conveniently and effectively for disease management. The improving healthcare infrastructure and awareness is further driving the demand for glucometers tailored to the diverse needs of the Asia Pacific population. For instance, in October 2023, the state governments of Mumbai (India) decision to permit students in Class 1-12 with Type-1 diabetes to consume snacks and medication and a glucometer in classrooms and examination halls was warmly received by schools, parents, and NGOs.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of diabetes worldwide
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Rising demand for self-monitoring devices globally
      • 3.2.1.4 Government initiatives for increasing awareness among people
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of advanced devices and accessories
      • 3.2.2.2 Lack of reimbursement and stringent regulations
  • 3.3 Growth potential analysis
  • 3.4 Technology landscape
  • 3.5 Porter's analysis
    • 3.5.1 Supplier power
    • 3.5.2 Buyer power
    • 3.5.3 Threat of new entrants
    • 3.5.4 Threat of substitutes
    • 3.5.5 Industry rivalry
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Self-monitoring blood glucose meters
  • 5.3 Continuous glucose monitors
    • 5.3.1 Wearable
    • 5.3.2 Non - wearable

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Type 1 diabetes
  • 6.3 Type 2 diabetes
  • 6.4 Gestational diabetes

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospital pharmacies
  • 7.3 Retail pharmacies
  • 7.4 Online sales
  • 7.5 Diabetes clinics & centers

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Poland
    • 8.3.7 Switzerland
    • 8.3.8 Sweden
    • 8.3.9 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Indonesia
    • 8.4.7 Thailand
    • 8.4.8 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Colombia
    • 8.5.5 Chile
    • 8.5.6 Peru
    • 8.5.7 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 Kuwait
    • 8.6.4 UAE
    • 8.6.5 Turkey
    • 8.6.6 Egypt
    • 8.6.7 Israel
    • 8.6.8 Qatar
    • 8.6.9 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 AgaMatrix
  • 9.3 All Medicus Co., Ltd.
  • 9.4 Ascensia Diabetes Care Holdings AG
  • 9.5 Arkray, Inc.
  • 9.6 B. Braun Melsungen AG
  • 9.7 Bionime Corporation
  • 9.8 DarioHealth Corporation
  • 9.9 Dexcom, Inc.
  • 9.10 Essenlife Bioscience, Inc.
  • 9.11 F. Hoffmann-La Roche Ltd.
  • 9.12 LifeScan Inc.
  • 9.13 Medtronic plc
  • 9.14 Nova Biomedical, Inc.
  • 9.15 Sinocare Inc.